复合异质合并性先天性蛋白C缺乏症:一个具有挑战性的管理,复发的紫色满症患者用蛋白C度治疗
Chonlatis Srichumpuang1,2,3, Phawin Kor-Anantakul4,5, Leonardo R Brandao6
1Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
BMJ case reports
|May 2, 2025
概括
严重的先天性蛋白C缺乏导致新生儿的渐进性死角性皮肤病变. 尽管有并发症,但早期诊断和使用新鲜冷血和肝素的治疗已经开始.
科学领域:
- 新生儿科学 新生儿科学
- 遗传学 是一个遗传学.
- 血液学 血液学 血液学
背景情况:
- 一名女新生儿出现了快速进展的死角性皮肤病变.
- 怀疑新生儿败血症的初始治疗是无效的,表明了潜在的疾病.
研究的目的:
- 报告一种严重的先天性蛋白C缺乏症病例,表现为广泛的皮肤亡.
- 为突出诊断挑战和管理策略这种罕见的疾病.
主要方法:
- 分析了临床表现和实验室发现.
- 基因测试在蛋白质C基因中发现了复合异构性变体.
- 治疗包括新鲜冷血 (FFP) 和低分子量肝素.
主要成果:
- 实验室测试显示,蛋白C活性和抗原水平严重下降.
- 分子分析证实了蛋白C基因中可能存在的致病变体.
- 患者在FFP治疗期间经历了包括急性损伤和高血压在内的并发症.
结论:
- 在新生儿中,严重的先天性蛋白C缺乏症可以表现为严重的皮肤亡.
- 及时诊断和管理至关重要,但治疗存在风险.
- 蛋白C度替代疗法是长期管理的一个重要考虑因素.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
89
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
89
Anticoagulant Drugs: Low-Molecular-Weight Heparins
536
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
536
Cystic Fibrosis: Management
94
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
94


